A feature of sulfonamide therapy for bacterial infections is that species of bacteria differ in their resistance to the antibacterial action of the compounds. It is also recognized that strains of microorganisms within the same species display variations in susceptibility. A disconcerting and confusing factor associated with chemotherapy, which appears to be assuming increasing clinical significance, is the ease and frequency with which some species of bacteria may develop in vtro and in vivo resistance to the bacteriostatic action of the sulfonamides. In the literature, the term "sulfonamide-fast" has been applied to those strains which become resistant to the antibacterial action of the compounds. This is particularly applicable to studies involving species of bacteria whose progenitors were known to be sensitive to the sulfonamides. Because the development of resistance is a relative phenomenon, and because, under proper experimental conditions, the growth of even the most resistant strains of bacteria may be inhibited by the drugs, the term "sulfonamide-resistant" is believed to be a more accurate description.
The purpose of this report is to review briefly the problem of sulfonamide-resistant bacteria in general, and to record the results of investigations with several strains of staphylococcus isolated from patients. An from patients and previous sulfonamide therapy carried out in these patients? Is the development of strain resistance a permanent characteristic of the bacteria?
Several species of bacteria have been rendered resistant to the in vitro and in vivo action of the sulfonamides. Many of the investigations have been carried out with different strains of the pneumococcus (1 to 5). Sesler and Schmidt (6) observed the development of sulfonamide-resistant pneumococci, and concluded that strains vary in developing this sulfonamide-resistance; that a given strain develops resistance to the several sulfonamides at different rates; that the more susceptible a parent strain is to the action of a sulfonamide, the more difficult it is to develop resistance; and that strains which become resistant to one sulfonamide, are resistant to all the other compounds tested. There is evidence that the development of sulfonamide-resistant pneumococci is more than a temporary phenomenon (7 to 9). On the other hand, sulfonamide-resistant pneumococci are sensitive to the action of specific antipneumococcus serum. Hemolytic streptococci, particularly Lancefield group A strains, are usually quite susceptible to the action of sulfanilamide, and yet strains in this group may acquire in vitro and in vivo resistance to the drug (10, 11) . While staphylococci as a species are more refractory to the bacteriostatic effect of all of the sulfonamides than are pneumococci and hemolytic streptococci, it has been demonstrated that strains of staphylococci may develop an increased resistance to the compounds (12, 13) . Gram-negative species of bacteria, whose growth is usually inhibited in vitro by the sulfonamides, have been shown to develop sulfonamide-resistance. These include E. coli (14, 15) , B. abortus (16) , meningococci (17) , and Shigella paradysentariae (strains of Flexner and Sonne) (18) . Strains of gono-cocci, a species which is highly susceptible to the bacteriostatic action of the sulfonamides, have been made resistant to sulfanilamide and sulfapyridine (19, 20) . Carpenter and his associates (21) could not develop an increased tolerance of 10 strains of gonococci to sulfathiazole over a period of 3 months. Nevertheless, this has been accomplished by Kirby (22) .
If invasive strains of microorganisms develop resistance to the sulfonamides both in vitro and in experimental animals, the question immediately arises as to whether such a phenomenon may transpire in human subjects while they are being treated with one of the sulfonamides, and whether the development of sulfonamide-resistant strains will (32) . Strains of staphylococci have been shown to develop sulfonamide-resistance in patients undergoing therapy with one of the sulfonamides (13) .
As a species, the staphylococcus is generally more resistant to the sulfonamides than are several other species of pyogenic bacteria. However (39) . Sodium sulfathiazole was selected for testing the resistance of the microorganisms. Comparative observations with sulfanilamide, sodium sulfapyridine, sodium sulfadiazine, and sodium sulfathiazole revealed that staphylococci were inhibited in their growth to a greater degree by sodium sulfathiazole than by the other sulfonamides. Furthermore, strains that were resistant to sodium sulfathiazole were more resistant to the aforementioned compounds. A water-clear medium of known chemical constituents, buffered to give a pH of 7.4, was employed in testing the staphylococci for their resistance to sodium sulfathiazole (40) . The preparation of this medium will be described below. As far as is known, this medium has a neglible amount of sulfonamide inhibitor. A standard in vitro test for sulfathiazole-resistance was used throughout. Strains to be tested were grown for several generations in the synthetic medium. As will be pointed out, variable results will be obtained if the initial inoculum of bacteria is not standardized. In performing the test, 10-fold dilutions of a 24-hour bacterial suspension were made in the synthetic medium. Then 0.1 cc. of the 10-8 dilution was added to each of several test tubes containing the synthetic medium. The approximate number of cocci seeded to each tube was determined by making duplicate agar pour plates with 0.1 cc. of the 10-7 dilution. A freshly prepared, aqueous solution of sodium sulfathiazole was used. Each strain was tested against varying concentrations of the compound. This was done by starting with an initial concentration of 1 mgm. per 100 cc. and then increasing the concentration of the drug in each of a series of tubes until a maximum concentration of 360 mgm.
was reached. The final total volume of each tube was 10 cc. The bacterial suspensions, with and without added sodium sulfathiazole, were incubated for 24 hours at 370 C.
At the end of this period, the degree of bacterial growth was determined according to the turbidity of the contents in each tube. Sulfathiazole-resistance was quantitated by selecting the tube which showed complete inhibition of bacterial growth with the lowest concentration of sodium sulfathiazole.
In a few instances, cultures of staphylococci were isolated from patients before they had been given a sulfonamide. In the remaining cases, this was not possible because chemotherapy had been instituted before the patients were seen.
INGREDIENTS AND PREPARATION OF SYNTHETIC MEDIUM
For the preparation of 50 liters of synthetic medium, the following weighed ingredients are mixed together in a large mortar. The mixture may then be stored in a clean container in the refrigerator until ready for further use. Table II . On the basis of many similar observations, the standard inoculum selected for use in all the comparative studies was 0.1 cc. of a 10-3 dilution of a 24-hour culture. The number of organisms in such an inoculum varied between 40,000 and 180,000 colonies. (Patient 18) appeared to benefit from such therapy. In summary then, although a group of patients had infections due to a strain of staphylococcus which was sensitive in vitro to sulfathiazole, and to a less extent to some of the other sulfonamides, no consistent and outstanding therapeutic results were obtained in 13 of 32 patients who were given one of the sulfonamides.
Attention is called to the fact that several of the strains listed in Table III were isolated from patients before it had been established at the University Hospitals that sulfonamide therapy might be of definite value in selected cases of staphylococcic sepsis. Cultures of many of these strains had been maintained on veal-agar slants under oil for several months before their in vitro susceptibility to sodium sulfathiazole was tested. It might be postulated that some of the parent cultures of these strains may have been sulfonamide-resistant, but during the course of many subcultures, this resistance became lost. Evidence will be presented to show that the acquisition of sulfonamide-resistance by staphylococci is more or less a permanent characteristic, and that this resistance does not disappear or diminish following many subcultures.
Correlation between strains of staphylococci moderately resistant to sodium sulfathiazole in vitro and the results of sulfonamide therapy A second series of 8 strains of staphylococcus were tested in vitro and all were found to be more resistant to sodium sulfathiazole. The results with this group are presented in Table IV . These strains required more than 1 mgm. per 100 cc. of sodium sulfathiazole and a concentration of less than 100 mgm. before growth was inhibited. In all but 3 cases (Patients 33, 37, and 40), a sulfonamide had been administered prior to isolation of the test strain. There is the possibility that Patients 37 and 40 received a sulfonamide before they were seen at the University Hospitals, but definite evidence is lacking.
In 2 of the patients (Patients 33 and 36), a culture of staphylococcus was isolated before chemotherapy, and then after a sulfonamide had been given. Patient 33 had a severe staphylococcic bacteremia associated with a thrombo- The results of therapy with sulfathiazole in the group of cases presented in Table IV 17 patients from whom these strains were isolated had had sulfonamide therapy prior to the isolation of the organisms. There is some evidence that the seventeenth patient had been given a sulfonamide. Although it cannot be concluded that the resistance of staphylococci to the inhibitory action of sodium sulfathiazole is due to previous sulfonamide therapy, it is obvious that the majority of the resistant strains were isolated from patients who had been given a sulfonamide.
Acquired sulfonamide-resistance a persistent characteristic All of the resistant strains of staphylococci included in this report have been subcultured numerous times on veal agar slants, and in synthetic medium, and in no instance did a strain lose its ability to resist the action of the sulfonamides. This relatively permanent feature of sulfonamide-resistance is emphasized by results obtained with strains 41 and 42. As noted in Table V (41) who showed that a Type I strain of sulfapyridine-resistant pneumococcus produced a substance which inhibited the action of sulfapyridine. Mirick (42) (43) . It should be emphasized that even the so-called non-resistant strains of staphylococcus produce p-aminobenzoic acid, but to a lesser degree than the resistant strains. There is some evidence at hand which would indicate that the more resistant strains of staphylococci produce relatively large amounts of p-aminobenzoic acid, especially in the presence of the sulfonamides (44) . While the mechanism whereby staphylococci resist the inhibitory action of the sulfonamides may be explained in part on the basis of the formation of p-aminobenzoic acid acting as a sulfonamide inhibitor, this mechanism does not necessarily apply to other species of bacteria. Recent evidence would indicate that another mechanism or mechanisms is responsible (9, 43) .
The use of the sulfonamides in the treatment of staphylococcic infections presents many problems. Even though in vitro tests may show that a particular strain of staphylococcus is susceptible to the action of a sulfonamide, attempts at therapy with this sulfonamide may be unsuccessful or not too satisfactory. This is related in large part to the nature of staphylococcic sepsis. Localized lesions, serving as foci for blood stream invasion, are made up of exudate, tissue necrosis, cellular debris, and dead organisms, all of which may inhibit the action of the sulfonamide. If, in addition to these factors, the organism becomes resistant to the sulfonamide, the likelihood of controlling an infection is further reduced. Another disturbing feature in our experience with staphylococcic infections is that sulfonamide-resistant strains of staphylococci are being encountered much more frequently at the present time than 2 or 3 years ago. This may be due to several factors. One is that the sulfonamides are being administered more freely to patients with staphylococcic sepsis before they are brought to the University Hospitals for further treatment. Another possibility is that sulfonamide-resistant strains are being disseminated because of the widespread use of the sulfonamides.
Particular attention should be given to the frequency with which sulfonamide-resistant strains of staphylococci were isolated from the urine of patients with varying types of urinary tract infections. In many cases, a low-grade infection was associated with obstruction to the flow of urine. The development of sulfonamide-resistant organisms is not to be taken too lightly, particularly if operative interference is contemplated. In one patient (Patient 43), a highly resistant strain of staphylococcus was obtained from the urine. This individual had benign prostatic hypertrophy with obstruction. Sulfonamides were administered prior to surgery, and following a transurethral prostatic resection, he developed a fatal staphylococcic bacteremia. The strain isolated from his blood was also resistant to the in vitro action of sulfathiazole, and therapy with this compound was of no value in controlling the infection. It is possible that the same sequence of events may take place in patients with other species of bacteria in the urinary tract as brought out in the following observation. Patient 49 developed a fatal bacteremia due to an anhemolytic strain of streptococcus, following a transurethral prostatic resection. This organism was cultured from the urine and the blood, and in vitro tests showed it to be highly resistant to sulfathiazole. It is of interest that, in 1926, Feirer and his associates (45) called attention to the development of "drug-fast" organisms in the urine against urinary antiseptics, which were derivatives of the heavy metals. On the basis of this observation, they suggested a rotation of drugs in the treatment of chronic urinary infections.
It is becoming more and more apparent that specific agents, other than the commonly used sulfonamides, are desirable in the treatment of patients with severe staphylococcic infections. There is increasing evidence that the antibiotic agents, such as penicillin, will yield more satisfactory clinical results. We have compared the in vitro action of sulfathiazole and penicillin. against the 57 strains given in this report, the results of which work will be presented elsewhere. It is significant that p-aminobenzoic acid does not inhibit the action of penicillin against the staphylococcus. On the other hand, staphylococci may develop in vitro resistance to penicillin, apparently by means of a different mechanism. This feature is undergoing investigation at the present time. SUMMARY 1. The problem of sulfonamide-resistant bacteria in general is briefly reviewed.
2. Fifty-seven strains of coagulase-positive staphylococci, isolated from an equal number of patients, were tested in vitro with a standard procedure against sodium sulfathiazole in a synthetic medium, containing negligible amounts of sulfonamide inhibitor. Thirty-two of the strains were considered non-resistant; 8 were moderately resistant; while 17 strains required a concentration of 100 mgm. per 100 cc. or more of sodium sulfathiazole. before growth was completely inhibited.
3. The acquisition of sulfonamide-resistance by staphylococci is a persistent characteristic of the organisms. 4 . Although it is apparent that sulfonamideresistant staphylococci do not necessarily develop as a result of the administration of the sulfonamides, the evidence presented in this paper indicates that resistant strains are almost always isolated from patients who have had previous sulfonamide therapy. 5 . The development of sulfonamide-resistance by staphylococci is dependent, at least in part, upon the elaboration of p-aminobenzoic acid by the bacterial cells.
